April 20, 2016
Otsuka Pharmaceutical Co., Ltd.
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of novel small molecule oncology therapeutics, announced on April 19 that it has entered into a clinical collaboration with Genentech.
The collaboration will evaluate the potential for combining Astex's next-generation hypomethylating agent, guadecitabine (SGI-110), with Genentech's investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML). An initial Phase 1b study will investigate the safety and pharmacology of the combination.
For more information about Astex Pharmaceuticals, please visit http://www.astx.com
Information in this news release was current as of the original release date.